Diffusion-Weighted MRI for Liver Metastasis

Inclusion Criteria

• •1. Contrast-enhanced thorax, abdomen and pelvic CT scan (with at least portal venous phase for the liver) at diagnosis and right before surgery are available
• •2. Multiparametric MRI at baseline and right before surgery are available (T1/T2, DW-MRI and contrast enhanced MRI).
• •3. WHO performance status of 0 or 1
• •4. Previous treatments (chemotherapy, surgery) for primary, liver and extra-hepatic metastases are allowed.
• •5. No other malignancies in the 3 years prior to study entry with the exception of surgically cured carcinoma in situ of the cervix, in situ breast cancer, incidental finding of stage T1a or T1b prostate cancer gleason score ≤ 6, and basal/squamous cell carcinoma of the skin
• •6. Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the study
• •Criteria for Enrollment
• •1. Conversion therapy is either being given or completed
• •2. Patient is suitable for hepatic resection based on the assessment of MDT composed of at least an expert liver/colorectal surgeon, Gastrointestinal (GI) radiologist and oncologist prior to any liver surgery
• •3. Hepatic resection is scheduled to take place within 8 weeks of latest imaging